MyFinsight
Home
Blog
About
Contact
Download
Download image
Unrealized income (loss) on
available for sale...
$873K
Comprehensive loss
-$80,257K
Total other
comprehensive income (loss)
$873K
Net loss
-$81,130K
Interest income
$13,354K
Loss before income
taxes
-$79,754K
Income tax (expense)
recovery (note 13)
$1,376K
Total other income,
net
$12,795K
Johnson And Johnson
Innovative...
$25,000K
Be One Medicines
Ltd.-Milestone Revenue
$20,000K
Be One Medicines
Ltd.-Recognition Of Deferred...
$18,334K
GSK-Milestone Revenue
$14,000K
Bristol Myers
Squibb-Option Exercise Fee
$7,500K
Drug Supply For
Ongoing Studies-Jazz
$6,548K
Jazz-Research Support
Payments And Other...
$5,616K
Daiichi Sankyo Co
Ltd-Milestone Revenue
$3,100K
Jazz-Royalty
$2,481K
Drug Supply-Jazz
$2,103K
Be One Medicines
Ltd.-Drug Supply
$762K
Be One Medicines
Ltd.-Royalty
$271K
Merck Sharp Dohme
LLC-Research Period...
$250K
Other (expense)
income, net (note 12)
-$559K
Loss from operations
-$92,549K
Research and development
collaborations (note 11)
$105,965K
Total operating
expenses
$198,514K
Research and development
$137,000K
General and
administrative
$61,514K
Back
Back
Income Statement
source: myfinsight.com
Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME)